Q3 2024 |
77 |
$2.55B |
+$52.2M |
-$198M |
-$146M |
MELI, FTI, HDB, IBN, HWM
|
13F-HR |
10/30/2024, 04:26 PM |
Q2 2024 |
74 |
$2.59B |
+$200M |
-$546M |
-$346M |
MELI, FTI, HDB, IBN, ASML
|
13F-HR |
8/14/2024, 08:37 AM |
Q1 2024 |
76 |
$2.9B |
+$114M |
-$570M |
-$455M |
MELI, FTI, IBN, TEAM, ASML
|
13F-HR |
5/6/2024, 10:11 AM |
Q4 2023 |
74 |
$3.11B |
+$239M |
-$330M |
-$91.3M |
MELI, FTI, APTV, ALKS, TEAM
|
13F-HR |
1/29/2024, 04:43 PM |
Q3 2023 |
75 |
$2.98B |
+$246M |
-$346M |
-$100M |
FTI, MELI, TEAM, BABA, ALKS
|
13F-HR |
10/20/2023, 10:03 AM |
Q2 2023 |
76 |
$3.08B |
+$101M |
-$216M |
-$114M |
FTI, ALKS, MLCO, IBN, MELI
|
13F-HR |
8/11/2023, 11:28 AM |
Q1 2023 |
73 |
$3.06B |
+$507M |
-$281M |
+$226M |
FTI, MLCO, ALKS, MELI, BABA
|
13F-HR |
5/5/2023, 02:06 PM |
Q4 2022 |
75 |
$2.55B |
+$283M |
-$251M |
+$31.8M |
FTI, IBN, MLCO, APTV, ALKS
|
13F-HR |
2/3/2023, 02:00 PM |
Q3 2022 |
77 |
$2.22B |
+$200M |
-$169M |
+$30.7M |
APTV, IBN, ALKS, MLCO, ASML
|
13F-HR |
11/2/2022, 10:33 AM |
Q2 2022 |
79 |
$2.36B |
+$92.1M |
-$275M |
-$182M |
APTV, IBN, ALKS, TEAM, MLCO
|
13F-HR |
8/2/2022, 04:36 PM |
Q1 2022 |
78 |
$3.11B |
+$121M |
-$236M |
-$115M |
IBN, APTV, TEAM, MLCO, ASML
|
13F-HR |
5/12/2022, 04:28 PM |
Q4 2021 |
77 |
$3.71B |
+$139M |
-$272M |
-$133M |
APTV, TEAM, IBN, MLCO, SE
|
Restatement |
3/23/2022, 04:34 PM |
Q3 2021 |
75 |
$3.72B |
+$226M |
-$645M |
-$418M |
IBN, APTV, TEAM, MLCO, SE
|
13F-HR |
11/12/2021, 12:50 PM |
Q2 2021 |
77 |
$4.13B |
+$439M |
-$117M |
+$322M |
TEAM, APTV, IBN, TSM, MLCO
|
13F-HR |
8/9/2021, 03:10 PM |
Q1 2021 |
77 |
$3.51B |
+$491M |
-$532M |
-$40.9M |
MLCO, APTV, IBN, TEAM, TSM
|
13F-HR |
5/12/2021, 11:03 AM |
Q4 2020 |
79 |
$3.45B |
+$574M |
-$127M |
+$447M |
TEAM, MLCO, BABA, APTV, IBN
|
13F-HR |
2/10/2021, 09:44 PM |
Q3 2020 |
76 |
$2.67B |
+$311M |
-$138M |
+$173M |
BABA, TEAM, MLCO, ASML, IBN
|
13F-HR |
11/13/2020, 09:01 PM |
Q2 2020 |
75 |
$2.27B |
+$341M |
-$127M |
+$214M |
BABA, MLCO, ASML, IBN, TEAM
|
13F-HR |
7/23/2020, 04:51 PM |
Q1 2020 |
73 |
$1.72B |
+$25M |
-$233M |
-$208M |
BABA, ASML, IBN, MLCO, MSFT
|
13F-HR |
5/4/2020, 04:41 PM |
Q4 2019 |
69 |
$2.48B |
+$108M |
-$153M |
-$44.4M |
BABA, IBN, MLCO, ASML, HDB
|
13F-HR |
2/5/2020, 03:10 PM |
Q3 2019 |
67 |
$2.18B |
+$107M |
-$50.7M |
+$56.4M |
BABA, IBN, MLCO, ASML, QGEN
|
13F-HR |
10/30/2019, 03:37 PM |
Q2 2019 |
70 |
$2.26B |
+$37M |
-$122M |
-$85M |
IBN, MLCO, BABA, QGEN, HDB
|
13F-HR |
8/5/2019, 03:46 PM |
Q1 2019 |
71 |
$2.28B |
+$138M |
-$142M |
-$4.25M |
MLCO, IBN, BABA, QGEN, HDB
|
13F-HR |
5/3/2019, 02:23 PM |
Q4 2018 |
69 |
$1.93B |
+$190M |
-$331M |
-$142M |
HDB, MLCO, BABA, QGEN, IBN
|
13F-HR |
2/6/2019, 02:00 PM |
Q3 2018 |
69 |
$2.32B |
+$89M |
-$123M |
-$33.9M |
AVGO, BABA, MLCO, HDB, QGEN
|
13F-HR |
10/17/2018, 05:50 PM |
Q2 2018 |
71 |
$2.37B |
+$291M |
-$356M |
-$65.3M |
HDB, AVGO, MLCO, BABA, QGEN
|
13F-HR |
7/18/2018, 03:56 PM |
Q1 2018 |
72 |
$2.35B |
+$199M |
-$222M |
-$23.5M |
HDB, AVGO, MLCO, BABA, ASML
|
13F-HR |
4/30/2018, 11:49 AM |
Q4 2017 |
72 |
$2.36B |
+$279M |
-$333M |
-$53.5M |
HDB, AVGO, BABA, MLCO, ASML
|
13F-HR |
1/26/2018, 03:29 PM |
Q3 2017 |
71 |
$2.34B |
+$39.8M |
-$136M |
-$95.7M |
HDB, BABA, AVGO, AGN, ASML
|
13F-HR |
10/30/2017, 04:13 PM |
Q2 2017 |
76 |
$2.32B |
+$228M |
-$268M |
-$39.6M |
HDB, AGN, AVGO, BABA, QGEN
|
Restatement |
8/14/2017, 10:20 AM |
Q1 2017 |
76 |
$2.23B |
+$153M |
-$230M |
-$76.6M |
AVGO, AGN, NXPI, HDB, MBBYF
|
13F-HR |
5/9/2017, 08:36 PM |
Q4 2016 |
77 |
$2.05B |
+$152M |
-$234M |
-$81.4M |
AVGO, NXPI, AGN, HDB, QGEN
|
13F-HR |
2/8/2017, 08:05 AM |
Q3 2016 |
78 |
$2.2B |
+$113M |
-$52.9M |
+$60.5M |
NXPI, AVGO, AGN, HDB, MBBYF
|
13F-HR |
10/24/2016, 11:09 AM |
Q2 2016 |
76 |
$1.96B |
+$305M |
-$79M |
+$226M |
NXPI, AVGO, AGN, MBBYF, HDB
|
13F-HR |
7/27/2016, 02:28 PM |
Q1 2016 |
77 |
$1.7B |
+$306M |
-$96.4M |
+$209M |
NXPI, BIDU, ASML, MBBYF, HDB
|
13F-HR |
5/2/2016, 11:07 AM |
Q4 2015 |
72 |
$1.51B |
+$138M |
-$188M |
-$49.9M |
QGEN, NXPI, BIDU, HDB, ASML
|
13F-HR |
2/9/2016, 04:30 PM |
Q3 2015 |
73 |
$1.5B |
+$54.1M |
-$71M |
-$16.9M |
QGEN, NXPI, HDB, ASML, BIDU
|
13F-HR |
11/10/2015, 11:43 AM |
Q2 2015 |
77 |
$1.67B |
+$73.7M |
-$66M |
+$7.68M |
NXPI, QGEN, BIDU, ASML, ETN
|
13F-HR |
8/11/2015, 08:12 AM |
Q1 2015 |
78 |
$1.66B |
+$142M |
-$410M |
-$268M |
NXPI, QGEN, BIDU, ASML, ETN
|
13F-HR |
5/8/2015, 06:55 AM |
Q4 2014 |
79 |
$1.85B |
+$233M |
-$209M |
+$23.7M |
NXPI, BIDU, QGEN, ASML, DEO
|
13F-HR |
2/4/2015, 12:57 PM |
Q3 2014 |
80 |
$1.81B |
+$117M |
-$121M |
-$3.81M |
NXPI, QGEN, ETN, ASML, DEO
|
13F-HR |
11/12/2014, 09:29 AM |
Q2 2014 |
81 |
$1.87B |
+$262M |
-$101M |
+$161M |
NXPI, DEO, QGEN, ASML, ETN
|
13F-HR |
8/12/2014, 10:10 AM |
Q1 2014 |
80 |
$1.71B |
+$295M |
-$78.2M |
+$217M |
DEO, ASML, ETN, NXPI, QGEN
|
13F-HR |
5/15/2014, 01:02 PM |
Q4 2013 |
78 |
$1.52B |
$0 |
$0 |
|
DEO, ASML, QGEN, MR, ADBE
|
13F-HR |
2/10/2014, 09:55 AM |